FORT LAUDERDALE, Fla., March 19, 2026 (GLOBE NEWSWIRE) — Kaida BioPharma, a biotechnology corporate growing centered remedies for ladies with hard-to-treat gynecologic cancers, nowadays introduced its govt management crew and board. Each and every member brings a long time of revel in in biotechnology, medical building, regulatory technique, production, finance, and commercialization to lend a hand advance Kaida’s lead product candidate, KAD-101, towards first-in-human medical analysis. The corporate is growing KAD-101 for recurrent ovarian most cancers, the place remedy choices slim briefly and sturdy keep watch over stays restricted.
Kaida BioPharma is construction KAD-101, a next-generation prolactin receptor antagonist for the ovarian most cancers hole, the distance the place sufferers are too steadily left biking thru remedy with too few sturdy choices.
Along with her position as Chairperson of the Board, Kaida founder Dr. Stella Vnook has been named Performing Leader Govt Officer. Dr. Vnook is an completed biotechnology founder, govt, and consultant with intensive revel in guiding early-stage therapeutics from medical basis thru capital formation. At Kaida, she leads company technique, building making plans, and investor engagement.
“The science brought me here, and the women out there still fighting are why I stay. At Kaida, we are building for the ovarian cancer gap, for patients whose options narrow too fast and whose disease still outpaces available therapies,” stated Dr. Vnook. “By targeting the survival signals that keep these tumors alive, we believe KAD-101 has the potential to help overcome treatment resistance and create a new path toward more durable control. More options mean more time, and more time means everything.”
Craig Pierson, a founder along Dr. Vnook, has been appointed Director at Kaida BioPharma. Mr. Pierson is a existence sciences investor and corporate builder with greater than 25 years of revel in in funding banking and personal capital formation. He supplies strategic oversight and financing experience.
George E. Peoples, MD, FACS has been appointed fractional Leader Scientific Officer. Dr. Peoples is a surgical oncologist with a long time of revel in in translational oncology and medical building. He’s additionally the founding father of the Most cancers Vaccine Construction Program, Most cancers Perception, and LumaBridge. At Kaida, he is helping information medical technique and IND making plans.
John Langenheim, PhD has been appointed fractional Leader Clinical Officer. Dr. Langenheim is a molecular biologist with greater than twenty years of revel in in healing protein design and preclinical building. His medical management has been instrumental in advancing KAD-101 towards medical analysis.
Pamela Swiggard has been appointed Head of Regulatory Affairs. She is a pharmaceutical govt with prior revel in at firms together with Pfizer and Endo Prescription drugs. She brings deep experience around the product lifecycle, from building thru regulatory approval and commercialization. At Kaida, she leads regulatory technique and FDA engagement in fortify of IND readiness for KAD-101.
Eric Hacherl, PhD has been appointed Head of Production. Dr. Hacherl is a senior pharmaceutical operations chief with greater than 25 years of revel in in biologics production, cGMP compliance, and procedure building. At Kaida, he’s answerable for serving to ensure that medical provide readiness for KAD-101.
Mark Sales space has been appointed Leader Industrial Officer. Mr. Sales space is a seasoned pharmaceutical and biotechnology govt with greater than 25 years of revel in construction industrial methods for oncology and uncommon illness merchandise. His background contains management throughout release making plans, emblem technique, get entry to, and marketplace building for vital oncology merchandise, together with EMEND, EMEND IV, Zolinza, vintafolide, KEYTRUDA, and the avutometinib plus defactinib mixture for low grade serous ovarian most cancers. At Kaida, he’s answerable for industrial technique for KAD-101, together with positioning, marketplace building, and long-term get entry to making plans.
About Kaida BioPharma
Kaida BioPharma is a biopharmaceutical corporate growing centered remedies for hormone-driven gynecologic cancers. Its lead candidate, KAD-101, is a prolactin receptor antagonist being evolved for recurrent ovarian most cancers, the place remedy choices slim briefly and lots of sufferers nonetheless face restricted sturdy keep watch over. Kaida is excited about construction cutting edge remedies for sufferers left within the ovarian most cancers hole and in different spaces of top unmet want. For more info, discuss with kaida-biopharma.com.
